Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Verubecestat in Hepatic Insufficiency
NCT02910739Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of verubecestat in Alzheimer's disease (AD) (4 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration Versus Time Curve From 0 to Infinity, Maximum Observed Plasma Concentration and 7 more. Started Oct 2016; status: completed.
02
Drugs
verubecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02910739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910739.